智飞生物(300122) - 2017 Q3 - 季度业绩预告

Financial Performance - The company expects net profit attributable to shareholders to be between 280 million and 295 million CNY for the first three quarters of 2017, representing an increase of 4041.22% to 4263.07% compared to the same period last year [2]. - In Q3 2017, the company anticipates a net profit of 108.21 million to 123.21 million CNY, recovering from a loss of 5.28 million CNY in Q3 2016 [3]. - The significant increase in profit is attributed to the recovery of vaccine sales following the resolution of uncertainties from the "3.18" vaccine industry incident, which had previously impacted sales [5]. - The company reports that the impact of non-recurring gains and losses on net profit is minimal, with expected growth in net profit excluding these items also between 4041.22% and 4263.07% [6]. - The financial data for the first three quarters of 2017 will be detailed in the company's Q3 report, as this earnings forecast is based on preliminary estimates [6].